Inducible nitric oxide synthase activation after ischemia/reperfusion contributes to myocardial dysfunction and extent of infarct size in rabbits: Evidence for a late phase of nitric oxide-mediated reperfusion injury

Cardiovascular Research

Volumn 43, Issue 3, 1999, Pages 698-711

  Wildhirt, Stephen M ^a   Weismueller, Susanne ^a   Schulze, Costas ^a   Conrad, Nicole ^a   Kornberg, Arno ^a   Reichart, Bruno ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Hemodynamics; Infarction; Nitric oxide; Regional blood flow; Reperfusion

Indexed keywords

AMINOGUANIDINE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PERFORMANCE; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REPERFUSION INJURY;

ADRENERGIC BETA-AGONISTS; ANIMALS; ENZYME ACTIVATION; ENZYME INHIBITORS; GUANIDINES; HEMODYNAMIC PROCESSES; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; ISOPROTERENOL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RABBITS; RANDOM ALLOCATION; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 0033566593     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00080-2     Document Type: Article

References (55)

1. Hansen P. Role of neutrophils in myocardial ichemia and reperfusion. Circulation. 91:1995;1872-1885.
2. Ferrari R., Ceconi C., Curello S., Alfieri O., Visioli O. Myocardial damage during ischemia and reperfusion. Eur. Heart J. 14:1993;25-30.
3. Lefer A., Lefer D. The role of nitric oxide and cell adhesion-molecules on the microcirculation in ischemia-reperfusion. Cardiovasc Res. 32:1996;743-751.
4. Horwitz L., Fennessey P., Shikes R., Kong Y. Marked reduction of myocardial infarct size due to prolonged infusion of an antioxidant during reperfusion. Circulation. 89:1994;1792-1901.
5. Schulz R., Wambolt R. Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischemia -reperfusion injury. Cardiovasc. Res. 30:1995;432-439.
6. Yasmin W., Strynadka K., Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc. Res. 33:1997;422-432.
7. Vinten-Johansen J., Sato H., Zhao Z.Q. The role of nitric oxide and NO-donor agents in myocardial protection from surgical ischemic - reperfusion injury. Int. J. Cardiol. 50:1995;273-281.
8. Kurose I., Wolf R., Grisham M.B., Granger D.N. Modulation of ischemia/reperfusion-induced microvascular dysfunction by nitric oxide. Circul. Res. 74:1994;376-382.
9. Woolfson R.G., Patel V.C., Neild G.H., Yellon D. Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation. 91:1995;1545-1551.
10. Finkel M., Oddis C., Jacob T., et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 257:1992;387-389.
11. Schulz R., Panas D., Catena R., et al. The role of nitric oxide in cardiac depression induced by interleukin-1β and tumour necrosis factor alpha. Br. J. Pharmacol. 114:1995;27-34.
12. Kelly R., Balligand J., Smith T. Nitric oxide and cardiac function. Circul. Res. 79:1996;363-380.
13. Wildhirt S., Suzuki H., Horstman D., et al. Selective modulation of inducible nitric oxide synthase in myocardial infarction. Circulation. 96:1997;1616-1623.
14. Hirono S., Islam M., Nakazawa M., et al. Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special refernce to changes in cardiac hemodynamics. Circ. Res. 80:1997;11-20.
15. Worrall N., Lazenby W., Misko T., et al. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J. Exp. Med. 181:1995;63-70.
16. Mattson S., Zeevi A., Cai J., et al. Effect of aminoguanidine and cyclosporine on lung allograft rejection. Ann. Thor. Surg. 62:1996;207-212.
17. Wu C., Chen S., Szabo C., Thiemermann C., Vane J. Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent model of septic shock. Br. J. Pharmacol. 114:1995;1666-1672.
18. Misko T., Moore W., Kasten T., et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidines. Eur. J. Pharmacol. 233:1993;119-125.
19. Dudek R.R., Wildhirt S.M., Conforto A., et al. Inducible nitric oxide synthase activity in myocardium after myocardial infarction in rabbit. Biochem. Biophys. Res. Commun. 205:1994;1671-1680.
20. Wildhirt S., Suzuki H., Wolf W., et al. S-methylisothiourea inhibits inducible nitric oxide synthase and improves left ventricular performance after acutr myocardial infarction. Biochem. Biophys. Res. Commun. 227:1996;328-333.
21. Joe E., Schussheim A., Longrois D., et al. Regulation of cardiac myocyte contractile dysfunction by inducible nitric oxide synthase (iNOS): Mechanisms of contractile depression by nitric oxide. J. Cellular Cardiol. 30:1998;303-315.
22. Beaven M., Gordon J., Jacobsen S., Severs W. A specific and sensitive assay for aminoguanidine: its application to a study of the disposition of aminoguanidine in animal tissues. J. Pharmacol. Exp. Therapeut. 165:1969;14-22.
23. Wildhirt S., Dudek R., Suzuki H., et al. Expression of nitric oxide synthase isoforms after myocardial infarction in humans. Endothelium. 3:1995;209-224.
24. Griffiths M., Messen T.M., Curzen N., Evans T. Aminoguanidine selectively decreases cyclic GMP levels produced by inducible nitric oxide synthase. Am. J. Resp. Crit. Care Med. 152:1995;1599-1604.
25. Foote E., Look Z., Giles P., Keane W., Halstenson C. The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis. Am. J. Kidney Dis. 25:1995;420-425.
26. Hare J., Givertz M., Ma C., Colucci W. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure. Potentiation of β-adrenergic inotropic responsiveness. Circulation. 97:1998;161-166.
27. Gardiner S.M., Kemp P.A., March J.E., Bennett T. Cardiac and regional hemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in concious, endotoxemic rats. Br. J. Pharmacol. 116:1995;2005-2016.
28. Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation and ischemia-reperfusion injury. Shock. 6:1996;79-88.
29. Liu P., Hock C., Nagele R., Wong P. Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats. Am. J. Physiol. 272:1997;H2327-H2336.
30. Buttery L., Springall D., Chester A., et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab. Invest. 75:1996;77-85.
31. Ma X., Lopez B., Liu G., Christopher T., Ischiropoulos H. Peroxynitrite aggravates myocardial reperfusion injury in the isolated perfused rat heart. Cardiovasc. Res. 36:1997;195-204.
32. Szabo C., Ferrer-Sueta G., Zingarelli B., et al. Mercaptoethylguanidin and guanidin inhibitors inhibtors of nitric oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage. J. Biol Chem. 272:1997;9030-9036.
33. Pantopoulos K., Hentze M.W. Nitric oxide signaling to iron-regulatory protein: direct control of ferritin mRNA translation and transferrin receptor nRNA stability in transfected fibroblasts. Proc Natl Acad Sci USA. 92:1995;1267-1271.
34. ++ and cell concentration in cultured chick ventricular myocytes. Circ. Res. 75:1994;285-295.
35. Kelly R., Smith T. Cytokines and cardiac contractile function. Circulation. 95:1997;778-781.
36. Quillen J., Sellke F., Brooks L., Harrison D. Ischemia-Reperfusion impairs endothelium-dependent relaxation of coronary microvessels but does not affect large arteries. Circulation. 82:1990;586-594.
37. Bolli R., Triana J., Jeroudi M. Prolonged impairement of coronary vasodilation after reversible ischemia. Evidence for microvascular stunning. Circ. Res. 67:1990;332-343.
38. Amrani M., Shirvani R., Allen N., Ledingham S., Yacoub M. Enhancement of low coronary reflow improves postischemic myocardial function. J. Thorac Cardiovasc Surg. 104:1992;1375-1382.
39. Seccombe J., Pearson P., Schaff H., Kennedy J. Oxygen radical-mediated vascular injury inhibits receptor-dependent release of nitric oxide from canine coronary arteries. J. Thorac Cardiovasc Surg. 107:1994;505-509.
40. Tsao P., Lefer A. Time course and mechanism of endothelial dysfunction in isolated ischemic- and hypoxic-perfused rat hearts. Am. J. Physiol. 259:1990;H1660-H1666.
41. Pernow J., Uriuda Y., Wang Q., et al. The protective effect of L-arginine on myocardial injury and endothelial function following ischemia and reperfusion in the pig. Eur. Heart J. 15:1994;1712-1719.
42. Hiramatsu T., Forbess J., Miura T., Mayer J. Effects of L-arginine and L-nitro-arginine methyl ester on recovery of neonatal lamb hearts after cold ischemia. J. Thorac Cardiovasc Surg. 109:1995;81-87.
43. Amrani M., Corbett J., Boateng S., Dunn M., Yacoub M. Kinetics of induction and protective effect of heat-shock proteins after cardioplegic arrest. Ann Thorac Surg. 61:1996;1407-1412.
44. Amrani M., Mankad P., Yacoub M. Imroved preservation of endothelial function at 4°C. Eur J. Cardiothorac Surg. 6:1992;72-78.
45. Avontuur J., Bruining H., Ince C. Nitric oxide causes dysfunction of coronary autoregulation in endotoxemic rats. Cardiovasc. Res. 35:1997;368-376.
46. Worral N., Chang K., Suau G., et al. Inhibition of inducible nitric oxide synthase prevents myocardial and systemic vascular barrier dysfunction during early cardiac allograft rejection. Circ. Res. 78:1996;769-779.
47. Joly G., Ayres M., Chelly F., Kilbourn R. Effects of N-methyl-L-ariginine, N-nitro-L-arginine and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun. 199:1994;147-154.
48. Ishiyama S., Hiroe M., Nishikawa T., et al. Nitric oxide contributes to the progression of myocardial damage in experimental myocarditis in rats. Circulation. 95:1997;489-496.
49. Yang X., Cai B., Sciacca R., Cannon P. Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circul. Res. 74:1994;318-328.
50. Tosaki A., Maulik N., Elliott G., et al. Preconditioning of rat heart with monophosphoryl lipid A: a role for nitric oxide. J. Pharmacol. Exp Ther. 285:1998;1274-1279.
51. Petros A., Lamb G., Leone A., et al. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res. 28:1994;34-39.
52. Elliott G. Monophosphoryl lipid A induces delayed preconditioning against ischemia-reperfusion injury. J. Mol Cell Cardiol. 30:1998;3-17.
53. Picard S., Parthasarathy S., Fruebis J., Witztum J. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci. 89:1992;6876-6880.
54. Requena J., Vidal P., Cabezas-Cerrato J. Aminoguanidine inhibits the modification of proteins by lipid peroxidation derived aldehydes: a possible antiatherogenic agent. Diabetes Res. 20:1992;43-49.
55. Bucala R., Makita Z., Vega G., et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci. 91:1994;9441-9445.